Yunu Unveils Next-Gen Trial Imaging with New eCRF Builder, Custom Dashboards & Universal Integration Portal
CARY, NC / ACCESS Newswire / May 29, 2025 / Yunu, the creator and leader in cloud-native imaging workflows for clinical trials, today announced a major new software release that empowers pharma sponsors to configure studies in minutes, enforce consistency, and deliver imaging data straight into their primary data systems - while simplifying work for site staff.
Yunu's unified cloud-SaaS platform powers end-to-end imaging workflows for thousands of clinical trials worldwide. From de-identification and site assessments to blinded reads with adjudication and real-time data delivery to sponsors, Yunu harmonizes multi-site trials, reduces complexity, and accelerates timelines, thereby reducing costs for both sponsors and sites. Expanding these capabilities, Yunu's new eCRF builder, enhanced sponsor dashboards, and native integration portal deliver a new realm of possibilities for trial sponsors who have previously been limited to inefficient and expensive manual workflows, long timelines, and disconnected data.
"To deliver better outcomes for patients, we have to be more protective of the imaging data that will define tomorrow's treatments," said Jeff Sorenson, CEO & Co-founder of Yunu. "With our new eCRF builder, intuitive dashboards, and seamless integration portal, sponsors gain full control over imaging endpoints - while sites benefit from a simpler, guided workflow and access to expert reading resources."
KEY SPONSOR BENEFITS
Rapid Customization of Imaging eCRFsProvides flexible capture of trial-specific data from directly within the QC and reading process, easily defined during the 30-minute study setup process, with no coding or delays.Real-Time Data, Custom Dashboards1,300+ standard data elements deliver unmatched context, traceability, and value with active monitoring of imaging schedules, scan availability, read status, and response rates across any combination of trials, therapeutic areas, participating sites, or endpoints.Seamless Data IntegrationThe Yunu integration portal supports user-defined and configured APIs, allowing for easy integration between other eClinical and data systems and your Yunu imaging source of truth. Imaging eCRF outputs and all other captured data are sent directly from Yunu into your clinical data warehouse or EDC system in real time - eliminating manual handoffs and file transfers.
SITE ADVANTAGES
Guided, Error-Free WorkflowsRadiologists, whether onsite or remote, follow the same step-by-step process, delivering complete, standardized, harmonized, protocol-conformant imaging endpoints that eliminate cumbersome and error-prone manual paper forms or spreadsheets.Faster Read TurnaroundBy streamlining end-to-end imaging workflows and data management tasks, Yunu frees up site staff to focus on patient care rather than paperwork.
All new features are available immediately to every Yunu customer and may be activated on any new or ongoing trial. Yunu will be exhibiting at the American Society of Clinical Oncology's (ASCO) Annual Meeting this weekend from Saturday, May 31st - Monday, June 2nd, at Booth #10080. Visit Yunu at ASCO or connect with the team by visiting yunu.io/contact-us.
ABOUT YUNUYunu enables life sciences organizations to streamline imaging workflows, improve accuracy, and accelerate timelines. Yunu's platform supports clinical trials across various therapeutic areas, offering scalability and flexibility for organizations of all sizes. For more information, visit yunu.io and follow us on LinkedIn or X @Yunu_Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
5 hours ago
- Business Insider
Regeneron announces analyses from Phase 3 C-Post trial
Regeneron (REGN) Pharmaceuticals announced detailed analyses from the Phase 3 C-POST trial, which evaluated PD-1 inhibitor Libtayo in patients with high-risk cutaneous squamous cell carcinoma, CSCC, after surgery. The results, shared during an oral session at the 2025 American Society of Clinical Oncology, ASCO, Annual Meeting and simultaneously published in the New England Journal of Medicine, NEJM, include additional data for the primary endpoint of disease-free survival, DFS, and the first presentation of key secondary endpoint outcomes. With a median duration of follow-up of 24 months, efficacy results for Libtayo compared to placebo, were as follows: 68% reduction in the risk of disease recurrence or death, with median DFS not reached for Libtayo-treated patients; At two years, DFS was 87% with Libtayo versus 64% with placebo; 80% reduction in the risk of locoregional recurrence; 65% reduction in the risk of distant recurrence
Business Insider
5 hours ago
- Business Insider
Replimune presents two posters on data updates for RP1 at 2025 ASCO
Replimune (REPL) Group presented two posters highlighting data updates for RP1 at the 2025 American Society of Clinical Oncology, ASCO, Annual Meeting taking place May 30-June 3 in Chicago. The poster included an analysis from the IGNYTE clinical trial of RP1 plus nivolumab in the cohort of anti-PD-1 failed melanoma patients. In the trial, the objective response rate was 32.9% using RECIST 1.1. The complete response rate was 15.0% and landmark overall survival rates at 1, 2, and 3 years were 75.3%, 63.3%, and 54.8% respectively. Median OS has not been reached. Patients experienced numerically higher objective response rates after receiving deep injections compared with superficial injections only. Deep responses were observed in injected and non-injected lesions. The ORR by injection type using RECIST 1.1 was 29.8% when only superficial lesions were injected, 42.9% for deep/visceral plus superficial injections injected, and 40.9% when only deep/visceral lesions were injected. There was a greater than or equal to30% reduction in 93.6% of injected lesions and 79.0% of non-injected lesions. Liver and lung injections had a tolerable safety profile. No bleeding events were reported after liver injection. Lung injections were associated with low rates of pneumothorax events, which were typically of low grade and manageable. Overall, these data support the safety and efficacy of deep/visceral injections and demonstrate the development of a robust systemic anti-tumor response following treatment with RP1 plus nivolumab.
Business Insider
5 hours ago
- Business Insider
Xilio Therapeutics announces updated Phase 2 data for vilastobart
Xilio Therapeutics (XLO) announced updated data from its ongoing Phase 2 clinical trial evaluating vilastobart, a tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4, in combination with atezolizumab in patients with metastatic MSS CRC. The data will be presented in a poster session at the American Society of Clinical Oncology, ASCO, Annual Meeting in Chicago. Results include: 26% preliminary objective response rate observed in heavily pre-treated patients with metastatic microsatellite stable colorectal cancer without liver metastases; Deep and durable responses ongoing for up to 37 weeks through the data cutoff, accompanied by substantial decreases in tumor biomarkers and improvements in clinical symptoms; MSS CRC patient with liver metastasis and previously reported confirmed partial response from Phase 1C remains on treatment after more than 14 months; combination continued to demonstrate differentiated safety and tolerability profile with low incidence of colitis and other immune-related adverse events Confident Investing Starts Here:
